Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Accumulated Depreciation (2019 - 2023)

Vaxcyte (PCVX) has 5 years of Accumulated Depreciation data on record, last reported at $9.3 million in Q4 2023.

  • On a quarterly basis, Accumulated Depreciation rose 51.58% to $9.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $9.3 million, a 51.58% increase, with the full-year FY2023 number at $9.3 million, up 51.58% from a year prior.
  • Accumulated Depreciation reached $9.3 million in Q4 2023 per PCVX's latest filing, up from $8.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for PCVX hit a ceiling of $9.3 million in Q4 2023 and a floor of $3.0 million in Q4 2019.
  • A 5-year average of $5.3 million and a median of $4.8 million in 2021 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: decreased 13.4% in 2021, then surged 72.41% in 2022.
  • Tracing PCVX's Accumulated Depreciation over 5 years: stood at $3.0 million in 2019, then skyrocketed by 37.39% to $4.1 million in 2020, then decreased by 13.4% to $3.5 million in 2021, then surged by 72.41% to $6.1 million in 2022, then surged by 51.58% to $9.3 million in 2023.
  • Business Quant data shows Accumulated Depreciation for PCVX at $9.3 million in Q4 2023, $8.4 million in Q3 2023, and $7.6 million in Q2 2023.